A recent report published by Infinium Global Research on cholesterol lowering drug market provides an in-depth analysis of segments and sub-segments in global as well as regional cholesterol lowering drug market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional cholesterol lowering drug market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global cholesterol lowering drug market. According to the report, the global cholesterol lowering drug market is projected to grow at a healthy CAGR over the forecast period of 2018-2024.
Cholesterol, a waxy, fat-like substance is important for the preparation of vitamin D, hormones, and substances that helps in the digestion of food. Low-density lipoproteins (LDL) and high-density lipoproteins (HDL) transmit cholesterol all over the body.HDL cholesterol, also known as good cholesterol is accountable for the removal of cholesterol from the body through the liver. LDL cholesterol, also known as bad cholesterol, starts to increase cholesterol in arteries causing atherosclerosis. Therefore, managing a proper balance between them is important for a healthy heart. Too much cholesterol in the blood can stick to the walls of the arteries. Blood clots appear around the plaques when these plaques start breaking and this result into the contraction of blood vessels and reduced oxygen-carrying capacity. Lack of exercise, growth in the intake of saturated and Trans fat, consumption of alcohol and smoking are main factors contributing to the increased occurrence of high cholesterol levels in patients. Irregular levels of cholesterol also occur owing to the existence of more than one condition such as kidney or liver disease, diabetes, polycystic ovary syndrome, pregnancy, underactive thyroid gland and other conditions which enhance the level of female hormones and drugs which raise LDL cholesterol and reduce HDL cholesterol.
Factors such as changes in lifestyle, growth in the intake of saturated and Trans fat and tobacco smoking are driving the growth of the Cholesterol-lowering drug market. Further, heredity can also be one of the reasons for high LDL levels in people with family hypercholesterolemia that results in the growth of the market for the same. In addition to this increasing occurrence of diabetes, kidney or liver disease underactive thyroid gland and other conditions among adults and aged population are also the major factors boosting the Cholesterol lowering drug market.
Among the geographies, Europe is the largest market for cholesterol lowering drugs followed by North America. In Europe region due to the high prevalence of hyperlipidemia among the people drives the market growth in this region. Moreover, sedentary lifestyle among the people influences the chances of increasing the cholesterol level, which in turn, increases the cholesterol lowering drug market. Further, in North America region factor such as growth in the unhealthy genes and lifestyles of people boost the growth of cholesterol lowering drugs market.
The report on global cholesterol lowering drug market covers segments such as a class of drugs. On the basis of a class of drugs, the global cholesterol lowering drug market is categorized into statins, fixed-dose combinations, cholesterol absorption inhibitors, ion exchange resins, fibrates, PCSK9 inhibitors, and novel cholesterol-lowering drugs.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while the Asia-Pacific region includes countries such as China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are the major markets included in the European region. The U.S. drives the growth in the North America region, as it is the largest market in the region. In the Asia-pacific region, rapid industrial growth in India and China offer a substantial potential for the growth in the cholesterol lowering drug market. As a result, the APAC region is projected to experience a growth at a CAGR of x.x% over the forecast period 2018-2024.
The report provides profiles of the companies in the global cholesterol lowering drug market such as AstraZeneca, Amgen, Merck and Co., Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Kowa Company, Ltd., AbbVie, Sanofi, and Novartis.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global cholesterol lowering drug market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of cholesterol lowering drug market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the cholesterol lowering drug market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the cholesterol lowering drug market to understand the present and future trends in this market and formulate their strategies accordingly.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter